Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
Identifieur interne : 002208 ( Main/Exploration ); précédent : 002207; suivant : 002209Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
Auteurs : Shin-Ichi Tamura [Japon] ; Yasuo Samegai [Japon] ; Hideki Kurata [Japon] ; Takashi Nagamine [Japon] ; Chikara Aizawa [Japon] ; Takeshi Kurata [Japon]Source :
- Vaccine [ 0264-410X ] ; 1988.
English descriptors
- Teeft :
- Adjuvant, Antibody, Antibody responses, Cholera, Cholera toxin, Control groups, Effecbve adjuvants, Effective adjuvants, Effectwe adjuvants, Immunol, Influenza, Influenza virus infection, Inoculated, Inoculated mtranasally, Inoculation, Intestinal mucosa, Lamina propna, Lung homogenate, Mouse, Mtranasal, Nasal, Nasal cavity, Nasal inoculation, Nasal mucosa, Nasal vaccination, Nasal vaccmatmn, Nasal wash, Nasal wash specimens, Oral tolerance, Other hand, Respiratory mucosa, Room temperature, Second inoculation, Separate assays, Toxin, Unrelated antigens, Vaccine, Vaccine effects, Valuable adwce.
Abstract
Abstract: Secretory IgA antibodies in mucosa are known to play an essential role in protection against various infectious agents1,2. To enhance the induction of protective mucosal antibodies, influenza HA vaccine was inoculated intranasally into mice with the B subunit of cholera toxin (CTB), which is known to be an excellent mucosal self-adjuvanting molecule3–6. This combination resulted in high levels of antiviral IgA antibodies in nasal secretions and enhanced serum haemagglutinin-inhibiting (HI) antibodies 4 weeks after inoculation, compared with the inoculation of vaccine alone which induced only a low level of HI serum antibodies and no local IgA antibodies. (Subcutaneous or intraperitoneal inoculation of the vaccine with CTB failed to induce detectable nasal antiviral IgA antibodies). Levels of nasal IgA and serum HI antibodies increased in a dose-dependent fashion with increasing nasal doses of both vaccine and CTB, and correlated with the degree of protection against viral challenge. A greater protective effect was seen with cholera toxin than with its B subunit. Moreover, a second administration of vaccine alone, 4 weeks after the inoculation of the vaccine with CTB, elevated the level of the antiviral IgA nasal antibodies to 10–100 times higher than that of the primary response. These results suggest that either CT or CTB could be used as a potent adjuvant to induce protective secretory antibodies by nasal vaccination against pathogens impinging on respiratory mucosa.
Url:
DOI: 10.1016/0264-410X(88)90140-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000889
- to stream Istex, to step Curation: 000889
- to stream Istex, to step Checkpoint: 000F21
- to stream Main, to step Merge: 002316
- to stream Main, to step Curation: 002208
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name></author><author><name sortKey="Samegai, Yasuo" sort="Samegai, Yasuo" uniqKey="Samegai Y" first="Yasuo" last="Samegai">Yasuo Samegai</name></author><author><name sortKey="Kurata, Hideki" sort="Kurata, Hideki" uniqKey="Kurata H" first="Hideki" last="Kurata">Hideki Kurata</name></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1CC2736C2B87D39A206CCFFC0DF40DF8E88F2E80</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0264-410X(88)90140-5</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-MF4B3XX3-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000889</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000889</idno><idno type="wicri:Area/Istex/Curation">000889</idno><idno type="wicri:Area/Istex/Checkpoint">000F21</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F21</idno><idno type="wicri:doubleKey">0264-410X:1988:Tamura S:protection:against:influenza</idno><idno type="wicri:Area/Main/Merge">002316</idno><idno type="wicri:Area/Main/Curation">002208</idno><idno type="wicri:Area/Main/Exploration">002208</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 2-10-35 Kamiosaki, Shinagawa-ku, Tokyo 141</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Samegai, Yasuo" sort="Samegai, Yasuo" uniqKey="Samegai Y" first="Yasuo" last="Samegai">Yasuo Samegai</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 2-10-35 Kamiosaki, Shinagawa-ku, Tokyo 141</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kurata, Hideki" sort="Kurata, Hideki" uniqKey="Kurata H" first="Hideki" last="Kurata">Hideki Kurata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 2-10-35 Kamiosaki, Shinagawa-ku, Tokyo 141</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Technology, The Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Technology, The Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 2-10-35 Kamiosaki, Shinagawa-ku, Tokyo 141</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">6</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="409">409</biblScope><biblScope unit="page" to="413">413</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Antibody</term><term>Antibody responses</term><term>Cholera</term><term>Cholera toxin</term><term>Control groups</term><term>Effecbve adjuvants</term><term>Effective adjuvants</term><term>Effectwe adjuvants</term><term>Immunol</term><term>Influenza</term><term>Influenza virus infection</term><term>Inoculated</term><term>Inoculated mtranasally</term><term>Inoculation</term><term>Intestinal mucosa</term><term>Lamina propna</term><term>Lung homogenate</term><term>Mouse</term><term>Mtranasal</term><term>Nasal</term><term>Nasal cavity</term><term>Nasal inoculation</term><term>Nasal mucosa</term><term>Nasal vaccination</term><term>Nasal vaccmatmn</term><term>Nasal wash</term><term>Nasal wash specimens</term><term>Oral tolerance</term><term>Other hand</term><term>Respiratory mucosa</term><term>Room temperature</term><term>Second inoculation</term><term>Separate assays</term><term>Toxin</term><term>Unrelated antigens</term><term>Vaccine</term><term>Vaccine effects</term><term>Valuable adwce</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Secretory IgA antibodies in mucosa are known to play an essential role in protection against various infectious agents1,2. To enhance the induction of protective mucosal antibodies, influenza HA vaccine was inoculated intranasally into mice with the B subunit of cholera toxin (CTB), which is known to be an excellent mucosal self-adjuvanting molecule3–6. This combination resulted in high levels of antiviral IgA antibodies in nasal secretions and enhanced serum haemagglutinin-inhibiting (HI) antibodies 4 weeks after inoculation, compared with the inoculation of vaccine alone which induced only a low level of HI serum antibodies and no local IgA antibodies. (Subcutaneous or intraperitoneal inoculation of the vaccine with CTB failed to induce detectable nasal antiviral IgA antibodies). Levels of nasal IgA and serum HI antibodies increased in a dose-dependent fashion with increasing nasal doses of both vaccine and CTB, and correlated with the degree of protection against viral challenge. A greater protective effect was seen with cholera toxin than with its B subunit. Moreover, a second administration of vaccine alone, 4 weeks after the inoculation of the vaccine with CTB, elevated the level of the antiviral IgA nasal antibodies to 10–100 times higher than that of the primary response. These results suggest that either CT or CTB could be used as a potent adjuvant to induce protective secretory antibodies by nasal vaccination against pathogens impinging on respiratory mucosa.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name></region><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><name sortKey="Kurata, Hideki" sort="Kurata, Hideki" uniqKey="Kurata H" first="Hideki" last="Kurata">Hideki Kurata</name><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><name sortKey="Samegai, Yasuo" sort="Samegai, Yasuo" uniqKey="Samegai Y" first="Yasuo" last="Samegai">Yasuo Samegai</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002208 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002208 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1CC2736C2B87D39A206CCFFC0DF40DF8E88F2E80
|texte= Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
}}
| This area was generated with Dilib version V0.6.33. |  |